Emerging evidence supports a mediator role for endothelin (ET)-1 in airway diseases including asthma. Respiratory tract viral infections, are associated with increased levels of ET and altered ET receptor density and function in murine airways. To determine whether these virus-induced effects are causally linked, perhaps involving ET-1-induced ET B receptor downregulation, the current study investigated the influence of in vivo administration of CGS 26303, an ET-converting enzyme inhibitor, on virus-induced changes in ET-content and ET B receptor density.CGS 26303 (5 mg . kg -1 . day -1) or placebo was administered to mice via osmotic minipumps implanted subcutaneously. Two days after implantation, mice were inoculated with influenza A/PR-8/34 virus or sham-infected, and all measurements were performed on tissue obtained on the fourth day post-inoculation.Viral infection was associated with elevated levels of immunoreactive ET and decreased densities of ET B receptors in murine airways. Both of these effects were attenuated in virus-infected mice that had received CGS 26303. Virus-induced increases in wet lung weight were also inhibited by CGS 26303. Importantly, administration of CGS 26303 had no effect on the titres of infectious virus in the lungs and similarly, viral infection had no effect on the plasma levels of free CGS 26303.In summary, CGS 26303 inhibited the virus-induced changes in both immunoreactive endothelin content and endothelin B receptor density. These findings are consistent with the postulate that the elevated epithelial expression of endothelin-1 during respiratory tract viral infection is a contributing factor in the downregulation of endothelin B receptors in airway smooth muscle. Whether inhibitors of endothelin synthesis attenuate virus-induced exacerbations of asthma or airways hyperresponsiveness remains to be established. Eur Respir J 1999; 14: 92±97. The levels of endothelin (ET)-1 in the airways are significantly elevated in respiratory diseases such as asthma [1] as well as in several animal models of airways disease, including allergic inflammation [2,3] and respiratory tract viral infection [4]. ET-1, via its potent actions on a raft of different cell types within the airways and lungs (for review see [5]), may contribute significantly to airway wall remodelling, oedema, bronchial obstruction, long-lasting bronchoconstriction and the development of airway hyperresponsiveness in asthma and during respiratory tract viral infections.Respiratory syncitial virus induces the expression of ET-1 in bronchial epithelial cells [6] and the levels of immunoreactive (ir)-ET-1 are elevated in murine airways and lung during influenza A viral infection [4]. Increases in the production of ET-1 by the airway epithelium would be expected to lead to enhanced stimulation of ET A and ET B receptors in adjacent tissues such as the airway smooth muscle. However, respiratory tract viral infection in mice was associated with reductions in ET B receptor density, which was reflected in attenuated...